Association of serum levels of antibodies against MMP1, CBX1, and CBX5 with transient ischemic attack and cerebral infarction.

作者：Wang, Hao; Zhang, Xiao-Meng; Tomiyoshi, Go; Nakamura, Rika; Shinmen, Natsuko; Kuroda, Hideyuki; Kimura, Risa; Mine, Seiichiro; Kamitsukasa, Ikuo; Wada, Takeshi; Aotsuka, Akiyo; Yoshida, Yoichi; Kobayashi, Eiichi; Matsutani, Tomoo; Iwadate, Yasuo; Sugimoto, Kazuo; Mori, Masahiro; Uzawa, Akiyuki; Muto, Mayumi; Kuwabara, Satoshi; Takemoto, Minoru; Kobayashi, Kazuki; Kawamura, Harukiyo; Ishibashi, Ryoichi; Yokote, Koutaro; Ohno, Mikiko; Chen, Po-Min; Nishi, Eiichiro; Ono, Koh; Kimura, Takeshi

来源：Oncotarget, 2018, 9(5): 5600-5613.

DOI：10.18632/oncotarget.23789

• Gerotarget
• SEREX
• TIA
• antibody biomarker
• atherosclerosis
• cerebral infarction

Transient ischemic attack (TIA) is a predictor for cerebral infarction (CI), and early diagnosis of TIA is extremely important for the prevention of CI. We set out to identify novel antibody biomarkers for TIA and CI, and detected matrix metalloproteinase 1 (MMP1), chromobox homolog 1 (CBX1), and chromobox homolog 5 (CBX5) as candidate antigens using serological identification of antigens by recombinant cDNA expression cloning (SEREX) and Western blotting to confirm the presence of serum antibodies against the antigens. Amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA) revealed that serum antibody levels were significantly higher in patients with TIA or acute-phase CI (aCI) compared with healthy donors (P < 0.01). Spearman's correlation analysis and multivariate logistic regression analysis demonstrated that levels of anti-MMP1, anti-CBX1, and anti-CBX5 antibodies were associated with age, cigarette-smoking habits, and blood pressure. Thus, serum levels of antibodies against MMP1, CBX1, and CBX5 could potentially serve as useful tools for diagnosing TIA and predicting the onset of aCI.

• 出版日期2018-1-19
• 单位CHIBA UNIVERSITY; 暨南大学